- Austria (Website)
- Czech Republic (Website)
- Denmark (Website)
- Finland (Website)
- France (Website)
- Germany (Website)
- Hungary (Website)
- Italy (Website)
- Ivory Coast
Lord Jim O’Neill joins bioMérieux in a knowledge exchange on the challenge of antimicrobial resistance07 March, 2018
Marcy l'Etoile, France, March 7, 2017 - bioMérieux, a world leader in infectious disease diagnostics, committed to the fight against antimicrobial resistance (AMR), organized today a panel discussion with Lord Jim O’Neill, an influential economist, politician and philanthropist who chaired the Review on Antimicrobial Resistance.
Marcy l'Etoile, France, March 7, 2017 - bioMérieux, a world leader in infectious disease diagnostics, committed to the fight against antimicrobial resistance (AMR), organized today a panel discussion with Lord Jim O’Neill, an influential economist, politician and philanthropist who chaired the Review on Antimicrobial Resistance. The discussions between Lord O’Neill and bioMérieux focused on the value of diagnostics to curb antimicrobial resistance through their ability to improve the appropriate use of antibiotics for improved patient management and reduced healthcare costs. The meeting was host to over one hundred bioMérieux experts in AMR and took place at the Company’s global headquarters in Marcy l’Étoile (France).
“bioMérieux has a longstanding expertise in antimicrobial resistance. A world leader in microbiology, the Company has developed a wide range of diagnostic solutions and services to address this important issue. True to its commitment to serve public health, bioMérieux provides healthcare professionals with essential information to take decisive action,” said Mark Miller, Corporate VP, Chief Medical Officer of bioMérieux. “We are honored to discuss with Lord Jim O’Neill today the role of diagnostics to combat antimicrobial resistance. We serve a common goal to leverage the power of diagnostics to reduce this global public health threat through optimized antibiotic use in order to preserve the efficacy of these treatments for future generations.”
A world leader in the field of in vitro diagnostics for 50 over years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion with over 90% of international sales.
bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market
(Symbol: BIM – ISIN: FR0010096479).
Reuters: BIOX.PA/Bloomberg: BIM.FP
Tel.: + 33 4 78 87 20 53
Tel.: + 1 216-407-5354
Tel.: + 33 1 53 70 74 64
Tel.: + 33 1 53 70 74 48
Download the Media Statement: